Sponsors
Program Chair’s Introduction and Welcome |
Session 1 |
Session 2 |
Session 3 |
Program Chair’s Summary and Vision Statement |
Amarin
A. Menarini Diagnostics
Amryt Pharmaceuticals
Chair – Prof Matthias Laudes
Speakers – Prof Francesco Giorgino, Prof Vaia Lambadiari
Agenda:
- Welcome and introduction (Prof Matthias Laudes)
- Diagnosis of severe insulin resistance and atypical diabetes and when to suspect lipodystrophy (Prof Francesco Giorgino)
- The management of lipodystrophy: clinical challenges and treatment opportunities (Prof Vaia Lambadiari)
- Q&A, conclusions (Prof Matthias Laudes)
Chair: Jiten Vora (UK)
Co-Chair: Nayyar Iqbal (AstraZeneca)
14:30 – 14:35 | Welcome | Elisabeth Björk (AstraZeneca) |
14:35 – 14:50 | Role of water conservation and metabolism in SGLT2 inhibitor mediated organ protection | Jens Marc Titze |
14:50 – 15:10 | Cracking the code in CKD: Mechanisms of renoprotection | Hiddo Heerspink |
15:10 – 15:30 | SGLT2 inhibitors in HF: Piecing together the puzzle of preserved ejection fraction | Sanjiv Shah (USA) |
15:30 – 15:40 | Panel discussion | All faculty |
15:40 – 15:55 | State of art lecture: NASH, disease burden and new opportunities – Emerging new modalities to manage NASH | Arun Sanyal (USA) |
15:55 – 16:00 | Closing remarks | Regina Fritsche-Danielson (AstraZeneca) |
Coming soon …
Coming soon …
Coming soon …
Chair: Jiten Vora (UK)
Speakers: TBC
Time (CEST) | Title | Speaker |
18:30–18:35 | Welcome and introductions | Jiten Vora |
18:35–18:45 | Addressing unmet needs in CKD and T2D with nonsteroidal MR antagonists | TBC |
18:45–19:00 | MR antagonism confers benefits irrespective of anti-diabetic agents or metabolic status: Insights from FIDELIO-DKD | TBC |
19:00–19:15 | FIGARO-DKD: Expanding the benefit of MR antagonism in CKD and T2D | TBC |
19:15–19:25 | Q&A | All faculty |
19:25–19:30 (5 min) | Summary and close | Jiten Vora |
17:40 – 17:45 | The case challenge | Melanie Davies (UK) |
17:45 – 17:55 | Defining treatment goals: SGLT2i, implications from clinical trials and guidelines | Nikolaus Marx (Germany) |
17:55 – 18:05 | Practical Challenges: SGLT2i in the spectrum of diabetes, CVD & CKD: Who and how to manage? | Melanie Davies (UK) |
18:05 – 18:10 | Discussion How to overcome clinical inertia? | Nikolaus Marx (Germany) |
Educational objectives
- To summarise the epidemiology and pathophysiology of patients with diabetes, CVD and CKD
- To discuss the role of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiorenal risk
- To address the remaining questions on the role of SGLT2 inhibition in the management of patients with diabetes and cardiorenal complications
- To provide an expert perspective on the clinical management of patients with type 2 diabetes, CKD and CV
Description:
Four experts in primary care, endocrinology, cardiology and nephrology will come together to discuss a patient-centred and evidence-based approach to care in T2D after metformin, offering their clinical perspectives on the optimal and multifactorial management of an evolving patient case
Faculty:
- John Buse (chair, USA)
- Kate Stevens (UK)
- Nikolaus Marx (Germany)
- Naresh Kanumilli (UK)
Dexcom
Eli Lilly and Company
Gan & Lee Pharmaceuticals
Coming soon…
Presenter:
Tobias Rohde, Sales Manager DACH
SUPPPORT STATEMENT
Supported by an independent educational grant from Novo Nordisk.
TARGET AUDIENCE
This activity is intended for diabetologists/endocrinologists, primary care physicians and cardiologists.
18:15 – 18:30 | The Endocrinologist in the Lead The Right Drug for the Right Patient at the Right Time |
18:30 – 18:45 | The Cardiologist in the Lead Primary and Secondary Cardiovascular Protection |
18:45 – 19:00 | The Primay Care Physician in the Lead Implementing Proactive Diabetes Care across the Stages |
19:00 – 19:15 | Panel Discussion and Q & A |
19:15 | Adjourn |
SUPPPORT STATEMENT
Supported by an independent educational grant from Lilly.
TARGET AUDIENCE
This activity is intended for diabetologists/endocrinologists and PCPs
08:15 – 08.25 | Better Metabolic Health with Incretin-based Therapies – Achievements and Ambitions |
08:25 – 08:40 | The Power of novel dual GIP/GLP-1 Receptor Agonists |
08:40 – 09:00 | The Clinical Evidence for GIP/GLP-1 Receptor Agonists – Assessing the Emerging Profile |
09:00 – 09:15 | Panel Discussion and Q & A |
09:15 | Adjourn |
SUPPORT STATEMENT:
Supported by an unrestricted educational grant from Amarin Pharma, Inc.
18:30 – 18:35 | Welcome, Introductions, Program Overview | Dirk Müller-Wieland |
18:35 – 18:55 | New Clinical Evidence of Omega-3 Fatty Acids on ASCVD Event Reduction | Dirk Müller-Wieland |
18:55 – 19:15 | Real-world Clinical Implications on Reducing ASCVD Events | Handrean Soran |
19: 15 – 19:30 | Panel Discussion and Q&A | Handrean Soran Dirk Müller-Wieland |
Closing Comments | Dirk Müller-Wieland | |
Learning Objectives
At the conclusion of this activity, learners should be better able to:
- Describe the spectrum of large-scale outcomes trials of omega-3 fatty acids on ASCVD events.
- Appreciate the differences between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements.
Chairs: Ofri Mosenzon (ISRAEL), Rich Pratley (US)
Faculty: Chris Cannon (US), David Cherney (CAN)
18:30- 18:33 Opening Remarks
(3 min) Speakers: Chairs (US)
18:33-18:41 ‘Highlighting the Patient with Diabetes and Cardiometabolic Disease’
(8 min) Speaker: Rich Pratley (US)
18:41 – 18:49 ‘Answering Unmet Needs – Clinical Understanding of Recent Heart Failure Data for Patients with Diabetes and Cardiovascular Disease’
(8 min) Speaker: Chris Cannon (US)
18:49 -18:57 ‘Adding to the Clinical Understanding for Patients with Diabetes and Cardio-renal Disease’
(8 min) Speaker: David Cherney (CAN)
18:57 – 19:27 ‘A Cross-Specialty Faculty Roundtable on Meeting the Needs of Patients with Diabetes and Established Cardiometabolic Disease: Are SGLT2is Best Utilized as a Cardiovascular Drug? A Kidney Drug? A Glycemic Lowering Agent? Or All of the Above?’
(30 Min) Speakers: Faculty
19:27 – 19:30 Closing Remarks
(3 min) Chairs
Faculty: David Cherney (CAN), Kim Connelly (CAN), Samuel Dagogo-Jack (US)
18:15- 18:20 Opening Remarks
(5 min) Speaker: Sam Dagogo-Jack (US)
18:20 – 18:43 ‘Cross-talk between the Heart, Kidneys & the Endocrine System – Understanding
(23 min) for Type 2 Diabetes and Cardiorenal Disease’
Speakers: David Cherney (CAN), Kim Connelly (CAN), Samuel Dagogo-Jack (US)
18:43- 18:45 Closing Remarks
(2 min) Speaker: Sam Dagogo-Jack (US)
14:30 – 14:35 | Welcome | Chair: Tina Vilsbøll (Denmark) |
14:35 – 14:47 | Should we have a more holistic treatment approach to improve healthy lifespan in people living with T2D? | Vanita Aroda (USA) |
14:47 – 15:10 | Panel discussion | Vanita Aroda (USA) |
15:10 – 15:20 | Treatment intensification in T2D with high-dose semaglutide: SUSTAIN FORTE | Juan Pablo Frias (USA) |
15:20 – 15:25 | Questions from the audience | |
15:25 – 15:27 | Welcome back | Chair: Tina Vilsbøll (Denmark) |
15:27 – 15:35 | The potential of semaglutide 2.4 mg for weight management | Rachel Batterham (UK) |
15:35 – 15:45 | Changing the paradigm in obesity care: the STEP 1–4 data | Melanie Davies (UK) |
15:45 – 15:55 | The clinical impact of double-digit weight loss | John Wilding (UK) |
15:55 – 16:08 | Questions from the audience | |
16:08 – 16:10 | Thanks and wrap-up | Chair: Tina Vilsbøll (Denmark) |
16:30 – 16:35 | Welcome | Chair: Tina Vilsbøll (Denmark) |
16:35 – 16:45 | Insulin innovations – the past: journey so far | Andreas Liebl (Germany) |
16:45 – 16:55 | Insulin innovations – the present: current scenario | Lena Landstedt-Hallin (Sweden) |
16:55 – 17:05 | Patient case study | Andreas Liebl (Germany) Lena Landstedt-Hallin (Sweden) |
17:05 – 17:20 | Insulin innovations – the future: roadmap to the future | Ronald Goldenberg (Canada) |
17:20 – 17:28 | Panel discussion | |
17:28 – 17:30 | Thanks and wrap-up | Chair: Tina Vilsbøll (Denmark) |
19:00 – 19:05 | Welcome | Chair: Tina Vilsbøll (Denmark) |
19:05 – 19:30 | Highlights and learnings: current diabetes and obesity management and future opportunities | |
09:15 – 09:20 | Overview of oral semaglutide and PIONEER trials | Filip K Knop (Denmark) |
09:20 – 09:30 | Case scenarios based on clinical evidence | Filip K Knop (Denmark) |
09:30 – 09:35 | Patient-centric practicalities | Vanita Aroda (USA) |
09:35 – 09:45 | A patient-centered approach with oral semaglutide Panel discussion and Q&A (live) |
17:40 – 17:55 | Introduction: | Kim Connelly (Canada) |
17:55 – 18:10 | STEPping forward: | Ildiko Lingvay (USA) |
18:10 – 18:25 | STEPping into the future: | Subodh Verma (Canada) |
18:25 – 18:40 | Live Q&A | Chaired by Kim Connelly (Canada) |
18:30 – 18:32 | Welcome | Athena Philis-Tsimikas (USA) |
18:32 – 18:35 | A retrospective look: | Simon Heller (UK) |
18:35 – 18:47 | Once-weekly basal insulins: | Athena Philis-Tsimikas (USA) |
18:47 – 18:53 | Patient-centric care: | Simon Heller (UK) |
18:53 – 18:58 | Questions from the audience | Facilitated by: Athena Philis-Tsimikas (USA) |
18:58 – 19:00 | Wrap-up | Athena Philis-Tsimikas (USA) |
09:15 – 09:35 | How and why to identify high-risk patients: lessons from the clinic | Elmar Jaeckel (Germany) |
09:35 – 09:45 | The future of NASH: the importance of interdisciplinary collaboration (interactive Q&A) | Elmar Jaeckel (Germany) |
17:40 – 17:43 | Welcome | Adie Viljoen (UK) |
17:43 – 17:51 | Early treatment: what are the benefits of early initiation of GLP-1RAs? | Tina Vilsbøll (Denmark) |
17:51 – 18:01 | Discussion session 1 | Tina Vilsbøll (Denmark) |
18:01 – 18:09 | Spotlight on: type 2 diabetes management for those with renal impairment | Tina Vilsbøll (Denmark) |
18:09 – 18:19 | Discussion and Q&A | Tina Vilsbøll (Denmark) |
18:19 – 18:27 | Spotlight on: glycaemic management in individuals with T2D and CVD | Matt Cavender (USA) |
18:27 – 18:37 | Discussion session 2 | Matt Cavender (USA) |
18:37 – 18:40 | A look at what is up and coming | Adie Viljoen (UK) |
Panda Insight
Roche Diabetes Care GmbH
Coming soon …
Coming soon …
Coming soon …
SANOFI
SUPPORT STATEMENT:
Supported by a Medical Education Grant from Gan & Lee
Chairs:
Vilsbøll, Tina (Denmark)
Heinemann, Lutz (Germany)
| 19:30 – 19:33 | Introduction | Vilsbøll, Tina (DNK) |
| 19:33 – 19:43 | Biosimilar Insulin Manufacturing: Why the process IS the product? | Heinemann, Lutz (GER) |
| 19:43 – 19:53 | Why do patient and HCP perceptions about biosimilar insulin matter? | Home, Philip (UK) |
| 19:53 – 20:00 | Discussion and closure | All |
SOOIL DEVELOPMENT
Tandem Diabetes Care, Inc.
Undermyfork
Speakers:
- Associate Professor Neale Cohen FRACP
Head Clinical Diabetes
Baker Heart and Diabetes Institute - Dr Martin de Bock FRACP PhD
Paediatric Endocrinologist
University of Otago and Canterbury District Health Board
